Upgrade to SI Premium - Free Trial

Neurocrine Bio. (NBIX) PT Raised to $100 at Oppenheimer

February 14, 2018 6:21 AM
Oppenheimer raised its price target on Neurocrine Bio. (NASDAQ: NBIX) to $100.00 (from $95.00) while maintaining a Outperform rating following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View Analyst PT Change

Next Articles